Science 37 (NASDAQ:SNCE) & ProMIS Neurosciences (OTCMKTS:ARFXF) Head to Head Contrast

Science 37 (NASDAQ:SNCEGet Rating) and ProMIS Neurosciences (OTCMKTS:ARFXFGet Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.


This table compares Science 37 and ProMIS Neurosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Science 37 N/A -146.10% -36.79%
ProMIS Neurosciences N/A N/A -27.60%

Institutional & Insider Ownership

28.0% of Science 37 shares are held by institutional investors. 4.4% of Science 37 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Science 37 and ProMIS Neurosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Science 37 N/A N/A -$560,000.00 N/A N/A
ProMIS Neurosciences $10,000.00 4,317.32 -$9.40 million ($0.02) -5.00

Science 37 has higher earnings, but lower revenue than ProMIS Neurosciences.

Risk & Volatility

Science 37 has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Science 37 and ProMIS Neurosciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Science 37 0 0 4 0 3.00
ProMIS Neurosciences 0 0 0 0 N/A

Science 37 currently has a consensus price target of $16.00, indicating a potential upside of 247.83%. Given Science 37’s higher possible upside, equities research analysts plainly believe Science 37 is more favorable than ProMIS Neurosciences.


Science 37 beats ProMIS Neurosciences on 5 of the 9 factors compared between the two stocks.

Science 37 Company Profile (Get Rating)

Science 37 Holdings, Inc. engages in the development of a technology platform to enable agile clinical trials and specialized networks to orchestrate trial execution. The company develops agile clinical trial operating system that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, medical device, and biotech companies. The company was formerly known as Science 37, Inc. and changed its name to Science 37 Holdings, Inc. in October 2021. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

ProMIS Neurosciences Company Profile (Get Rating)

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformÂProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AÃO); and PMN330, a monoclonal antibody targeting toxic prion-like forms of AÃO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Receive News & Ratings for Science 37 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science 37 and related companies with's FREE daily email newsletter.